

# PAVE Library: relevant scientific publications and media coverage

## WEBSITE

- *P. vivax* information hub: [EN](#) | [SPA](#)
- Vivax malaria Study Database: [EN](#) | [SPA](#)
- The Partnership for Vivax Elimination: [EN](#) | [SPA](#)
- Tafenoquine Roll-Out Study (TRuST): [EN](#) | [SPA](#) | [PT](#)
- Peru feasibility study: [EN](#) | [SPA](#)
- Colombia G6PD Pilot Educational Program (PEP): [EN](#) | [SPA](#)

## SCIENTIFIC PUBLICATIONS

### Publications on Radical Cure (EN):

- Malaria Journal: **Challenges for achieving safe and effective radical cure of *Plasmodium vivax*: a round table discussion of the APMEN Vivax Working Group** (2017)
- **Towards the elimination of *Plasmodium vivax* malaria: Implementing the radical cure** (2021)
- **The prevention and treatment of *Plasmodium vivax* malaria** (2021)
- **Primaquine for *Plasmodium vivax* radical cure: What we do not know and why it matters** (2021)

### Publications on Radical Cure in Latin America (EN):

- **Towards one standard treatment for uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* malaria: Perspectives from and for the Peruvian Amazon** (2021)

### Evidence on primaquine (EN):

- Malaria Journal: **Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group** (2018)
- New England Journal of Medicine: **Higher-Dose Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria** (2022)
- The Lancet Infectious Diseases: **Primaquine dose and the risk of haemolysis in patients with uncomplicated *Plasmodium vivax* malaria: a systematic review and individual patient data meta-analysis** (2023)
- The Lancet Infectious Diseases: **Effect of primaquine dose on the risk of recurrence in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis** (2023)

### Evidence on tafenoquine (EN):

- New England Journal of Medicine: **Tafenoquine – A Radical Improvement?** (2019)
- New England Journal of Medicine: **Single- Dose Tafenoquine to Prevent Relapse of *Plasmodium vivax* Malaria** (2019)

- New England Journal of Medicine: **Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria** (2019)
- Pubmed: **Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with *Plasmodium vivax* malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial** (2021)
- The Lancet Child & Adolescent Health: **Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with *Plasmodium vivax* malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial** (2022)
- The Lancet: **Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of *Plasmodium vivax* malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study** (2023)

#### **Additional publications on tafenoquine (EN):**

- Journal of Travel Medicine: **Tafenoquine and G6PD: a primer for clinicians** (2019)
- Current Opinion in infectious diseases: **Tafenoquine: the new kid on the block** (2019)
- Cochrane Library: **Tafenoquine for preventing relapse in people with *Plasmodium vivax* malaria** (2020)
- PLoS Medicine: **Estimated impact of tafenoquine for *Plasmodium vivax* control and elimination in Brazil: A modelling study** (2021)
- PLoS Medicine: **Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study** (2021)

#### **Evidence on the G6PD test (EN):**

- American Journal of Trop. Medicine and Hygiene: **Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient** (2018)
- PLoS One: **Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity** (2018)
- PLoS Neglected Tropical Diseases: **Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil** (2021)
- PLoS Neglected Tropical Diseases: **Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis** (2023)
- MBPI: **Assessing the Operational Feasibility of Integrating Point-of-Care G6PD Testing into Plasmodium vivax Malaria Management in Vietnam** (2023)

#### **Additional publications on the G6PD test (EN):**

- International Journal of Neonatal Screening: **Point-of-care Testing for G6PD Deficiency: Opportunities for Screening** (2018)
- Malaria Journal: **Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation** (2021)
- PLoS: Neglected Tropical Diseases: **Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study)** (2021)
- Malaria Journal: **Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia** (2022)

## EVIDENCE BRIEFS

- Pediatric treatment for *P. vivax* malaria: new positive data: [EN](#) | [SPA](#) | [PT](#)
- New treatment for *P. vivax* malaria may benefit Brazilian public health: [EN](#) | [SPA](#) | [PT](#)
- Evaluation of a point-of-care test for G6PD deficiency in Brazil: [EN](#) | [PT](#)
- Point-of-care G6PD diagnostics: [EN](#) | [SPA](#) | [PT](#)

## MEDIA – ABOUT PAVE

- New Partnership launched to accelerate elimination of relapsing *P. vivax* malaria that poses a risk to an estimated 2.5 billion people worldwide: [EN](#)
- Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research: [EN](#) | [SPA](#)
- PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria: [EN](#)

MEDIA – ABOUT *P. VIVAX* IN LATIN AMERICA

- What does it take to eliminate malaria?: [PT](#)
- Exploring new tools for *P. vivax* elimination in Brazil: [EN](#) | [PT](#)
- PAVE Regional Meeting Highlights: 2020: [EN](#) | [SPA](#); 2021: [EN](#) | [SPA](#) | [PT](#); 2022: [EN](#) | [SPA](#) | [PT](#)

## MEDIA – ABOUT TQ &amp; G6PD TEST

- Preparing the ground in the Brazilian Amazon: [PT](#)
- New medicine to treat malaria starts to be used in Amazonas: [EN](#)
- PATH and SDB announce partnership to advance diagnostic test critical for malaria treatment and elimination: [EN](#)

## MEDIA – REGULATORY MILESTONES

- US FDA approves Krintafel (tafenoquine) for the radical cure of *P. vivax* malaria: [EN](#)
- Kozenis (tafenoquine) approved by Australian TGA for the radical cure of *P. vivax* malaria: [EN](#)
- Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of *P. vivax* malaria: [EN](#)
- New single-dose medicine to prevent relapse of *P. vivax* malaria just approved in Peru: [EN](#) | [SPA](#)
- Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration: [EN](#) | [SPA](#) | [PT](#)

- **STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration: [EN](#)**
- **Colombia approves single-dose medicine to prevent relapse of *P. vivax* malaria: [EN](#) | [SPA](#) | [PT](#)**
- **Brazil's Unified Health System incorporates tafenoquine as a treatment for malaria: [EN](#) | [PT](#)**
- **Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria: [EN](#) | [SPA](#) | [PT](#)**

## MEDIA – FEASIBILITY STUDIES

- **First real-world use of new protocol for *P. vivax* case management in Brazil – a Health Ministry and MMV collaboration: [EN](#)**
- **Peru feasibility study: First patient, First visit: [EN](#)**